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LETTERS TO THE EDITOR
Gemcitabine-Induced
Acute Eosinophilic
Pneumonia
To the Editor:
Gemcitabine (GEM), an analogue
of deoxycytidine, is a pyrimidine antime-
tabolite with broad preclinical and clinical
antitumor activity. It is activated by de-
oxycytidine kinase and incorporated into
DNA, resulting in chain termination.
GEM is active in a variety of solid
tumors, including pancreatic cancer,
non-small cell lung cancer (NSCLC),
breast cancer, biliary tract cancer, bladder
cancer, and ovarian cancer.1 Various pul-
monary toxicities can be caused by GEM;
however, there has been no report of acute
eosinophilic pneumonia (AEP). Herein,
we report a case of AEP induced by the
administration of GEM.
The patient was a 77-year-old
never-smoking woman diagnosed with
NSCLC (adenocarcinoma) 2 years previ-
ously. Her clinical stage was T2N2M0
(stage IIIA). She received concurrent che-
moradiotherapy consisting of four cycles
of carboplatin  paclitaxel and 60 Gy
thoracic irradiation, and achieved a partial
response. One year later, she developed
recurrence and pemetrexed was adminis-
tered as her second-line chemotherapy;
however, her disease progressed after
eight cycles of pemetrexed. Thereafter,
GEM was selected for her third-line che-
motherapy. GEM was given at a dose of
1000 mg/m2 on days 1, 8, and 15 every 4
weeks. From the start of GEM, her blood
eosinophil concentration increased contin-
uously (Figure 1). In addition, chest com-
puted tomography after two cycles of
GEM revealed diffuse ground-glass opac-
ity in both lungs. Although she presented
with a slight cough, she had no fever, and
her blood oxygen level was normal (85.0
Torr in room air). We then performed
bronchofiberscopy to obtain a definite di-
agnosis. Bronchoalveolar lavage (BAL)
revealed a high concentration of eosino-
phils: eosinophils, 83.4%; macrophages,
13.0%; lymphocytes, 2.6%; and neutro-
phils, 1.0%. Transbronchial lung biopsy
showed the accumulation of eosinophils
within the alveolar space (Figure 2), and a
diagnosis of AEP was made. When bron-
chofiberscopy was performed, the blood
concentration of eosinophils was already de-
creasing, and diffuse ground-glass opacity
on the chest computed tomography was im-
proving. Thereafter, both her blood eosino-
phil concentration and chest abnormal
shadow normalized spontaneously.
Although GEM-induced severe pul-
monary toxicities are uncommon, accord-
ing to the most recent analysis of a large
database, GEM-induced pneumonitis has
been reported to occur in up to 13.8% of
patients with NSCLC.2 There have been
reports of various pulmonary complica-
tions associated with GEM, such as pul-
monary edema, acute respiratory distress
syndrome, diffuse alveolar damage, dif-
fuse alveolar hemorrhage, and pulmonary
effusion3; however, to our knowledge, this
is the first case of AEP induced by GEM.
Peripheral blood eosinophil per-
centages are usually normal; however, a
very high percentage of BAL eosinophils
is characteristic of AEP.4 AEP usually
shows a good response to steroid therapy
and rarely leads to respiratory failure, and
spontaneous regression is also reported in
some cases, as in our case.5 When patients
treated with GEM present with an abnor-
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FIGURE 1. Time-dependent change of white blood cells and eosinophils in the
blood. Solid arrows indicate the administration of gemcitabine. Dashed arrow indi-
cates the timing of bronchofiberscopy.
FIGURE 2. Microscopic findings of this case. A, A low magnification view of the
biopsy specimen from the right middle lobe of the lung shows a patchy highly cel-
lular area in the lung parenchyma. B, At higher power magnification, eosinophils
(arrow), alveolar macrophages, and fibrous exudates are seen within the alveolar
space accompanied by reactive type II pneumocyte hyperplasia (arrowhead). There
are no microorganisms, neoplastic change, vasculitis, or granuloma.
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mal chest shadow, AEP should be consid-
ered in the differential diagnosis, and BAL
and/or transbronchial lung biopsy should be
performed to obtain a definite diagnosis.
Young Hak Kim, MD
Michiaki Mishima, MD, PhD
Department of Respiratory Medicine
Graduate School of Medicine
Kyoto University, Sakyo-Ku
Kyoto, Japan
Akihiko Yoshizawa, MD, PhD
Department of Diagnostic Pathology
Kyoto University Hospital, Sakyo-ku
Kyoto, Japan
REFERENCES
1. Thomas A, Steward WP. Gemcitabine—a ma-
jor advance? Ann Oncol 1998;9:1265–1267.
2. Barlesi F, Villani P, Doddoli C, et al. Gem-
citabine-induced severe pulmonary toxicity.
Fundam Clin Pharmacol 2004;18:85–91.
3. Camus P, Fanton A, Bonniaud P, et al. Inter-
stitial lung disease induced by drugs and ra-
diation. Respiration 2004;71:301–326.
4. Jeong YJ, Kim KI, Seo IJ, et al. Eosinophilic
lung diseases: a clinical, radiologic, and
pathologic overview. Radiographics 2007;27:
617–637, discussion 37–39.
5. Philit F, Etienne-Mastroianni B, Parrot A, et
al. Idiopathic acute eosinophilic pneumonia: a
study of 22 patients. Am J Respir Crit Care
Med 2002;166:1235–1239.
Prospective Study of
Lambert-Eaton
Myasthenic Syndrome
in Small Cell Lung
Cancer
To the Editor:
Small cell lung cancer (SCLC) is a
highly immunogenic tumor of neuroendo-
crine origin. Autoantibodies to tumor-as-
sociated antigens have been detected in up
to 68% of patients with SCLC,1 some-
times present before the presence of
symptomatic disease. The presence of au-
toantibodies has also been linked to prog-
nosis in lung cancer, although it is not
clear whether the presence of a host’s
immune response to tumor antigens im-
proves overall survival. In patients with
autoimmune paraneoplastic neurologic
disorders (PNDs), the identification of dis-
tinct clinical syndromes such as Lambert-
Eaton myasthenic syndrome (LEMS),
usually evident before tumor detection,
has been linked in retrospective studies to
improved survival compared with patients
with SCLC without PNDs.2 However, it is
not clear whether it is the lead-time bias in
detecting lung tumors early or an effect on
the tumor from circulating antibodies
(such as voltage-gated calcium channel
antibodies [VGCC] in LEMS) that im-
proves long-term survival.
We read with interest the report by
Payne et al.,3 which detailed their pro-
spective study of patients with SCLC to
establish the incidence of PNDs such as
LEMS in this cohort. They found 2 of 63
patients with SCLC (3%) had LEMS,
which was discovered concomitantly at
the time of SCLC diagnosis. A further
three patients had detectable VGCC an-
tibodies but no associated LEMS or
other PNDs. It was reported that multi-
variate analysis (Cox regression) was
used to evaluate the survival: the pres-
ence of VGCC was not associated with
improved survival, although their two
LEMS cases survived for 23.5 and 15.5
months. We suspect that they are correct
in their assumption that the study was
underpowered to detect an effect on sur-
vival from the presence of VGCC anti-
bodies, although they do not specify
what size of hazard ratio their study
was underpowered. Their data records
showed very low case recruitment rates
(an average of only six new SCLC cases
recruited each year for 10 years) and in-
cluded a larger proportion of males (73%)
than would be expected in a contemporary
SCLC cohort. In addition, a large number
of their study patients (86%) had extensive
disease. Because gender and disease stage
are well-established prognostic factors,
any bias of the study population toward
over-representation of a particular sub-
group may have affected their survival
statistics, and in particular the apparent
effect of VGCC antibodies if such prog-
nostic factors were not taken into account
in this analysis. There also seems to be an
error in reporting because the hazard ratio
is given as 0.999 yet has a rather implau-
sible p value of 0.08.
It is not clear from their report
whether Payne et al. have underestimated
the true incidence of LEMS in their cohort
of patients with SCLC. LEMS is almost
always identified before tumor discovery,
and such patients may not have ultimately
enrolled in their study after subsequent
SCLC diagnosis. With such low rates of
recruitment of patients with SCLC, there
may have been a number of patients in
their 10-year study period who developed
PNDs with SCLC but were not enrolled.
One of us (P.M.) has recently pub-
lished the first 100 cases in an ongoing,
prospective study of patients with SCLC
designed to determine whether the pres-
ence of onconeural antibodies, with or
without PNDs (including LEMS), is as-
sociated with a favorable prognosis.4
That study found a slightly higher inci-
dence of LEMS (4%) and a similar num-
ber of additional SCLC patients with
VGCC antibodies but no neurologic
symptoms (6%) even after follow-up.
When taking into account the additional
prognostic factors such as age, gender,
and disease extent, there was a slightly
better (not statistically significant) over-
all survival in VGCC antibody positive
patients. We suspect that the true value
of this ongoing prospective study will be
to differentiate whether the previously
reported improvement in survival of pa-
tients with LEMS and SCLC from ret-
rospective studies2 is due to the clini-
cian’s lead-time bias rather than an
effect of the VGCC antibodies them-
selves. As of February 2010, we have
enrolled 240 SCLC patients over a
4-year period, of whom 9 have LEMS
and VGCC antibodies and 11 have
VGCC antibodies but no associated
LEMS. Median survival time is 13.25
months among LEMS patients and
11.25 months for all patients with
VGCC antibodies. In 177 of our SCLC
study patients who had no PND or de-
tectable onconeural antibodies, the me-
dian survival is only 8.5 months. If it is
demonstrated that survival is improved
not only in LEMS patients with SCLC
but also in patients with VGCC antibod-
ies but no signs of LEMS, this may
indicate that it is the immunoreactivity
to tumor antigens such as VGCCs that is
contributing to better survival, perhaps
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